BSEInsider Trading / SAST26 Sept 2026
Ishita Drugs & Industries Ltd
The trading window for dealing in securities of the company by designated persons stands closed from Thursday, 01st Octomber, 2026 till 48 hours after the declaration of the Unaudited Financial statements for the quarter ended 30th September, 2026.
Ishita Drugs & Industries Ltd has closed its trading window for designated persons from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.
BSECompany UpdateDebt Restruc.22 Sept 2026
Ishita Drugs & Industries Ltd
Pursuant to the Regulation 30read with Schedule III of SEBI(LODR) Regulations, 2015, we wish to inform you that Ishita Drugs and Industries Limited has entred into loan agreement with HDFC Bank Limited.
Ishita Drugs & Industries Ltd has entered into a loan agreement with HDFC Bank Limited to raise funds for financing the upgradation project for its manufacturing facility at Sanand, Dist. Ahmedabad, Gujarat.
BSEBoard MeetingDebt Restruc.22 Sept 2026
Ishita Drugs & Industries Ltd
we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, held its meeting today i.e. Tuesday, 22nd September, 2026, has, Approved the borrowings from the HDFC Bank Limited.
Ishita Drugs & Industries Ltd has approved borrowings from HDFC Bank Limited amounting to Rs. 11.75 crore, comprising a term loan of Rs. 9.75 crore and a working capital facility of Rs. 2 crore.
BSECompany Update31 Aug 2026
Ishita Drugs & Industries Ltd
Company has issued letters providing a weblink of Company''s website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
Ishita Drugs & Industries Ltd has issued letters to shareholders who have not registered their email addresses, providing a weblink to access the Annual Report for Financial Year 2025-26.
BSEOthersResults27 Aug 2026
Ishita Drugs & Industries Ltd
Annual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
Ishita Drugs & Industries Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the Notice of 33rd Annual General Meeting to be held on 30th September 2026.
BSEAGM/EGMMgmt Change27 Aug 2026
Ishita Drugs & Industries Ltd
Notice of 33RD AGM of the Company which will be held on wednesday, 30th September, 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
Ishita Drugs & Industries Ltd has announced the 33rd Annual General Meeting (AGM) to be held on September 30, 2026, with e-voting period from September 27 to 29, 2026. The meeting will consider re-appointment of auditors, related party transactions, and other business.
BSEAGM/EGM27 Aug 2026
Ishita Drugs & Industries Ltd
The E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
Ishita Drugs & Industries Ltd has announced the e-voting period for its 33rd AGM, scheduled to be held on 30.09.2026. The e-voting period will commence from 27.09.2026 and ends on 29.09.2026.
BSECorp. Action27 Aug 2026
Ishita Drugs & Industries Ltd
Register of Members and Share transfer book of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days Inclusive) for the purpose of 33rd Annual General Meeting of the Company.
Ishita Drugs & Industries Ltd has announced the book closure for its 33rd Annual General Meeting (AGM) from September 24, 2026, to September 30, 2026, inclusive.
BSECompany UpdateMgmt Change8 Aug 2026
Ishita Drugs & Industries Ltd
Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
Ishita Drugs & Industries Ltd has announced the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director of the Company post attaining the age of 75 years. The Board of Directors also approved the Unaudited Financial Results for the quarter ended 30th June, 2026, and accepted the revised remuneration proposal of Mr. Sumit Agrawal, Chief Financial Officer of the Company. The meeting also discussed the upgradation project of the manufacturing facility for compliance with Revised Schedule M.
BSEResultResults8 Aug 2026
Ishita Drugs & Industries Ltd
Unaudited Financial Results of the Compmany for the quarter ended 30th June, 2026 along with limited review report issued by statutory auditor.
Ishita Drugs & Industries Ltd announced unaudited financial results for the quarter ended 30th June, 2026, along with a limited review report from the statutory auditor. The board approved the results, re-appointed a director, and discussed the upgradation project of the manufacturing facility.
BSEBoard MeetingResults8 Aug 2026
Ishita Drugs & Industries Ltd
Outcome of the Board meeting held on 08th August, 2026.
Ishita Drugs & Industries Ltd's board meeting outcome: approved unaudited financial results for Q1 2026, re-appointed Mrs. Abha Agrawal as non-executive non-independent director, approved revised remuneration for CFO, discussed upgradation project of manufacturing facility, and amended notice for 33rd AGM.
BSEBoard MeetingResults31 Jul 2026
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve 1. To consider, approve ....
Ishita Drugs & Industries Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 to consider and approve the unaudited financial results for the quarter ended 30th June, 2026.